Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01770 |
| Species: | Homo sapiens |
| Position : | chr12:11718965-11902194 |
| Year: | 2024 |
| Title: | ETV6::ACSL6 translocation-driven super-enhancer activation leads to eosinophilia in acute lymphoblastic leukemia through IL-3 overexpression. |
| Genome Build: | hg19 |
| Enhancer Type: | Super-enhancer |
| Condition: | Disease |
| Disease Name: | B-cell acute lymphoblastic leukemia |
| PMID: | 38356460 |
| MONDO: | MONDO:0004947 |
| Tissue: | bone marrow |
| Tissue Ontology ID: | UBERON:0002371 |
| Cell Source: | Primary ETV6::ACSL6 B-ALL cells (RJ-9) |
| Cell Type: | precursor B cell |
| Cell Ontology ID: | CL:0000817 |
| Experiment Type: | Super-enhancer activity assay; Enhancer hijacking assay; Chromatin interaction assay; In vivo functional validation |
| High Throughput Method: | Hi-C; RNA-seq; H3K27ac CUT&Tag; H3K4me1 CUT&Tag; BRD4 CUT&Tag; Oxford Nanopore long-read sequencing |
| Low Throughput Method: | Luciferase Reporter Assay (HEK293T; Pro-SE1-derived 3-kb element); In vivo phenotyping; Xenograft/xenotransplant |
| Target gene : | ACSL6 |
| TF name : | NA |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|